Anna Rada, Lea Marie Reisch, Anne Hagemann, Friedrich G Woermann, Christian G Bien
{"title":"Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies: Defining a Distinct Epilepsy Syndrome.","authors":"Anna Rada, Lea Marie Reisch, Anne Hagemann, Friedrich G Woermann, Christian G Bien","doi":"10.1212/NXI.0000000000200422","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Epilepsy associated with glutamic acid decarboxylase antibodies (GAD-abs) often presents as temporal lobe epilepsy (TLE). However, detailed data on this condition are lacking. The aim of this study was to demonstrate that TLE with GAD-abs (GAD-TLE) is distinct from other forms of TLE and to describe the subgroup of patients with epilepsy and GAD-abs but no evidence of TLE.</p><p><strong>Methods: </strong>Inpatients from 2011 to 2022 with high serum GAD-abs (≥1:80, confirmed by a cell-based assay and typical staining pattern on a tissue-based assay) were included. The control group comprised patients with mesial TLE (EMU-mTLE) with hippocampal sclerosis or nonlesional epilepsy diagnosed on the epilepsy monitoring unit (EMU) and having negative results on a broad panel of neural antibodies. Data were retrospectively collected from first admission (visit 1 [V1]) and most recent follow-up (visit 2 [V2]). Parameters included demographic data, comorbidities, seizure characteristics, electroencephalography findings, MRI results, verbal memory performance, GAD-ab titers (V1), therapies, seizure and memory outcomes, and occupational status (V2).</p><p><strong>Results: </strong>Of 81 GAD-ab-positive patients, 71 (88%) had TLE. Compared with 40 EMU-mTLE controls, patients with GAD-TLE were more often female (84% vs 33%, <i>p</i> < 0.001), more frequently had autoimmune comorbidities (46% vs 2.5%, <i>p</i> < 0.001), musicogenic seizures (18% vs 0%, <i>p</i> = 0.004), and seizure clusters (25% vs 5%, <i>p</i> = 0.002) but less frequently had hippocampal sclerosis (25% vs 54%, <i>p</i> = 0.007). At follow-up (GAD-TLE: median 5 years; EMU-mTLE: 2 years), only 14% of patients with GAD-TLE were terminally seizure-free for ≥1 year, compared with 39% of patients with EMU-mTLE (<i>p</i> = 0.04). Verbal memory remained stable, and occupational status was unchanged. Ten GAD-ab-positive cases without evidence of TLE were identified, including 3 with generalized features.</p><p><strong>Discussion: </strong>Epilepsy associated with GAD-abs predominantly manifests as TLE and as such is an epilepsy syndrome (GAD-TLE). In comparison with EMU-confirmed patients with mTLE without GAD-abs, the seizure outcome is inferior but the neuropsychological performance is usually normal and remains stable. A subset of patients with epilepsy with high-titer GAD-abs do not have TLE, some presenting with generalized features.</p>","PeriodicalId":19472,"journal":{"name":"Neurology® Neuroimmunology & Neuroinflammation","volume":"12 4","pages":"e200422"},"PeriodicalIF":7.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166559/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology® Neuroimmunology & Neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXI.0000000000200422","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Epilepsy associated with glutamic acid decarboxylase antibodies (GAD-abs) often presents as temporal lobe epilepsy (TLE). However, detailed data on this condition are lacking. The aim of this study was to demonstrate that TLE with GAD-abs (GAD-TLE) is distinct from other forms of TLE and to describe the subgroup of patients with epilepsy and GAD-abs but no evidence of TLE.
Methods: Inpatients from 2011 to 2022 with high serum GAD-abs (≥1:80, confirmed by a cell-based assay and typical staining pattern on a tissue-based assay) were included. The control group comprised patients with mesial TLE (EMU-mTLE) with hippocampal sclerosis or nonlesional epilepsy diagnosed on the epilepsy monitoring unit (EMU) and having negative results on a broad panel of neural antibodies. Data were retrospectively collected from first admission (visit 1 [V1]) and most recent follow-up (visit 2 [V2]). Parameters included demographic data, comorbidities, seizure characteristics, electroencephalography findings, MRI results, verbal memory performance, GAD-ab titers (V1), therapies, seizure and memory outcomes, and occupational status (V2).
Results: Of 81 GAD-ab-positive patients, 71 (88%) had TLE. Compared with 40 EMU-mTLE controls, patients with GAD-TLE were more often female (84% vs 33%, p < 0.001), more frequently had autoimmune comorbidities (46% vs 2.5%, p < 0.001), musicogenic seizures (18% vs 0%, p = 0.004), and seizure clusters (25% vs 5%, p = 0.002) but less frequently had hippocampal sclerosis (25% vs 54%, p = 0.007). At follow-up (GAD-TLE: median 5 years; EMU-mTLE: 2 years), only 14% of patients with GAD-TLE were terminally seizure-free for ≥1 year, compared with 39% of patients with EMU-mTLE (p = 0.04). Verbal memory remained stable, and occupational status was unchanged. Ten GAD-ab-positive cases without evidence of TLE were identified, including 3 with generalized features.
Discussion: Epilepsy associated with GAD-abs predominantly manifests as TLE and as such is an epilepsy syndrome (GAD-TLE). In comparison with EMU-confirmed patients with mTLE without GAD-abs, the seizure outcome is inferior but the neuropsychological performance is usually normal and remains stable. A subset of patients with epilepsy with high-titer GAD-abs do not have TLE, some presenting with generalized features.
期刊介绍:
Neurology Neuroimmunology & Neuroinflammation is an official journal of the American Academy of Neurology. Neurology: Neuroimmunology & Neuroinflammation will be the premier peer-reviewed journal in neuroimmunology and neuroinflammation. This journal publishes rigorously peer-reviewed open-access reports of original research and in-depth reviews of topics in neuroimmunology & neuroinflammation, affecting the full range of neurologic diseases including (but not limited to) Alzheimer's disease, Parkinson's disease, ALS, tauopathy, and stroke; multiple sclerosis and NMO; inflammatory peripheral nerve and muscle disease, Guillain-Barré and myasthenia gravis; nervous system infection; paraneoplastic syndromes, noninfectious encephalitides and other antibody-mediated disorders; and psychiatric and neurodevelopmental disorders. Clinical trials, instructive case reports, and small case series will also be featured.